Taiwan
· Delayed Price · Currency is TWD AP Biosciences Company Description
AP Biosciences, Inc. researches and develops protein and antibody drugs for unmet medical needs.
It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinical research phase for treating lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors.
It caters to healthcare and biotechnology industries. The company was founded in 2013 and is based in Taipei, Taiwan.
| Country | Taiwan |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Jeng-Horng Her |
Contact Details
Address: No.508, Zhongxiao East Road Taipei, 115011 Taiwan | |
| Phone | 886 2 2653 2886 |
| Website | apbioinc.com |
Stock Details
| Ticker Symbol | 6945 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006945009 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeng-Horng Her Ph.D. | Founder, Chief Executive Officer, GM and Director |
| Fucheng Huang | Director of Accounting and Finance and Head of Corporate Governance |
| Tseng Winnie | Director of Administration |
| Qiying Yang | Director of Legal Department |
| Jhong-Jhe You Ph.D. | Vice President of Antibody Discovery |
| Weilun Lo | Vice President of Business Development |
| Qiqiang Tu | Director of Biologics Development |
| Yihong Ou | Director of Bioengineering |